CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.
If you are eligible, you may be able to lower your out-of-pocket costs for STELARA®, including deductible, co-pay, and coinsurance medication costs. With Janssen CarePath Savings Program for STELARA®, eligible patients pay just $5 per dose for their STELARA® medication costs, with a $20,000 maximum program benefit each calendar year. Patients using Medicare, Medicaid or any other federally-funded programs to pay for STELARA® are not eligible to participate in the program. Before the calendar year ends, you will receive information and eligibility requirements for continued participation in the program. There is no income requirement.
Given these considerations, antipsychotic drugs should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that 1) is known to respond to antipsychotic drugs, and 2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.